Model‐Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non–Small Cell Lung Cancer

Nivolumab is the first anti–programmed death‐1 agent approved in China for treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC). Here, we characterize the population pharmacokinetics (PPK) of nivolumab monotherapy in Chinese patients with previously treated advanced/recurre...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jason, Cai, Junliang, Bello, Akintunde, Roy, Amit, Sheng, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767401/
https://www.ncbi.nlm.nih.gov/pubmed/31115908
http://dx.doi.org/10.1002/jcph.1432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767401/
https://www.ncbi.nlm.nih.gov/pubmed/31115908
http://dx.doi.org/10.1002/jcph.1432

Ejemplares similares